Skip to main content

Golden State Medical Supply Inc.

Recalls

Recalls by year

A bar chart of the number of recalls naming this company by year.

Recalls by year
YearRecalls
20141
20153
20167
20183
201911
20204
20213
20228
20234
20243
20253
20263
Download CSV

FDA Recall Terminated Historical recordClass II

ARIPIPRAZOLE TABLETS, 15 mg, 30-count. bottles, Rx Only, GSMS Incorporated, Manufactured by: Apotex Inc. Toronto, Ontario, Canada, Packaged by GSMS, Incorporated, Camarillo, CA 93012 USA, NDC #60429-449-30

by Golden State Medical Supply Inc.

Reason
FAILED DISSOLUTION SPECIFICATIONS: Possibility of out-of-specification (OOS) dissolution limits for the remaining shelf life of the Aripiprazole Tablets
Published
December 9, 2020
Distribution
Nationwide

View recall →

FDA Recall Terminated Historical recordClass III

Clobetasol Propionate Cream, USP, 0.05%, packaged in a)15g Tubes (NDC 60429-902-15) and b) 45g Tubes (NDC 60429-902-45), Rx Only, Mfd. by: Taro Pharmaceuticals Inc. Brampton, Ontario, Canada, Marketed by: Golden State Medical Supply Inc. Camarillo, CA 93012.

by Golden State Medical Supply Inc.

Reason
Failed Content Uniformity: bulk lot used to make these two lots was found to have failed content uniformity.
Published
August 19, 2020
Distribution
Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Losartan Potassium Tablets, USP, 25 mg, Rx only, a) 30 ct. (NDC 60429-316-30) b) 90ct. (NDC 60429-316-90) c) 1,000 ct. (60429-316-10) bottles, GSMS Incorporated, Manufactured by Arrow Pharm (Malta) Ltd., Packaged by GSMS Incorporated, Camarillo, CA 93012, USA

by Golden State Medical Supply Inc.

Reason
CGMP Deviations: Impurity for N-nitroso-N-methyl-4-aminobutryric Acid (NBMA) detected in active ingredient (API) used to manufacture finished products.
Published
April 22, 2020
Distribution
Nationwide

View recall →

FDA Recall Terminated Historical recordClass III

TRAMADOL HYDROCHLORIDE Tablets, USP, 50 mg, Rx Only a)100-count bottles (NDC 60429-588-01) b) 500-count bottle (NDC 60429-588-05) Manufactured by Teva Czech Industries, s.r.o. Opava-Komarov, Czech Republic, Packaged by GSMS Incorporated, Camarillo, CA 93012

by Golden State Medical Supply Inc.

Reason
Labeling: Incorrect package insert - Patient leaflets for the specified lots of unscored tablets contain language relative to a 25 mg dosing titration that necessitates the use of a scored 50 mg tablet.
Published
March 4, 2020
Distribution
Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

GSMS: Ranitidine Capsules 300 mg, Rx only, 100 count bottles (NDC 51407-098-01) Manufactured by Novitium Pharma LLC, 70 Lake Drive, East Windsor, New Jersey 08520; Packaged by GSMS, Incorporated, Carmillo, CA 93012 USA.

by Golden State Medical Supply Inc.

Reason
CGMP Deviations: Presence of NDMA impurity detected in product.
Published
November 20, 2019
Distribution
Multiple states

View recall →

FDA Recall Terminated Historical recordClass II

GSMS: Ranitidine Capsules 150 mg, Rx only, 500 count bottles (NDC 51407-097-05) Manufactured by Novitium Pharma LLC, 70 Lake Drive, East Windsor, New Jersey 08520; Packaged by GSMS, Incorporated, Carmillo, CA 93012 USA.

by Golden State Medical Supply Inc.

Reason
CGMP Deviations: Presence of NDMA impurity detected in product.
Published
November 20, 2019
Distribution
Multiple states

View recall →

FDA Recall Terminated Historical recordClass II

Losartan Potassium, 100 mg tablets, 90 count bottle, NDC 60429-318-90

by Golden State Medical Supply Inc.

Reason
CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
Published
July 17, 2019
Distribution
Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Losartan Potassium, 50 mg tablets, 1000 count bottle, NDC 60429-317-10

by Golden State Medical Supply Inc.

Reason
CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
Published
July 17, 2019
Distribution
Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Losartan Potassium, 50 mg tablets, 90 count bottle, NDC 60429-317-90

by Golden State Medical Supply Inc.

Reason
CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
Published
July 17, 2019
Distribution
Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Losartan Potassium, 50 mg tablets, 30 count bottle, NDC 60429-317-30

by Golden State Medical Supply Inc.

Reason
CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
Published
July 17, 2019
Distribution
Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Losartan Potassium Tablets USP 100 mg 1000 count bottle NDC 60429-318-10 Rx only GSMS Incorporated

by Golden State Medical Supply Inc.

Reason
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer
Published
May 29, 2019
Distribution
IL, MI, MN, PA, TN, TX. Two (2) US gover…

View recall →

FDA Recall Terminated Historical recordClass II

Losartan Potassium Tablets USP 100 mg 90 count bottle NDC 60429-318-90 Rx only GSMS Incorporated

by Golden State Medical Supply Inc.

Reason
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer
Published
May 29, 2019
Distribution
IL, MI, MN, PA, TN, TX. Two (2) US gover…

View recall →

This page lists recalls that name Golden State Medical Supply Inc. as the recalling firm in the official source notice. It is not a safety rating, ranking, or statement that the company acted negligently. Read the full medical disclaimer.